Ligachem Biosciences signs iADC joint research, licensing deal with Abion

Bitget2026/09/30 08:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ligachem Biosciences signed a joint research and license agreement with South Korea’s Abion on Sept. 30, 2026.
Deal targets iADC, combining Abion’s interferon beta mutein immunocytokine-antibody with Ligachem’s ADC platform via a linker-payload conjugation.
Ligachem secured worldwide exclusive rights to develop and commercialize iADC candidates across up to five targets it selects.
Payments include an upfront for target-selection exclusivity, research funding, target-based milestones, sales-based royalties; financial terms were not disclosed.
Company flagged the agreement as conditional, with continuation tied to R&D and clinical outcomes; it can be terminated under specified conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ligachem Biosciences Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260930900659), on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ligachem Biosciences signs iADC joint research, licensing deal with Abion

You may also like

Crypto prices